Preconceptional Sex Selection Techniques — CPB 0323 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0323 governing preconceptional sex selection techniques, effective September 26, 2025. Here's what billing teams need to know before submitting claims under flow cytometry codes 88182–88189 and reproductive procedure codes 58321, 58322, and S4011–S4042.

Aetna's CPB 0323 Aetna system update draws a hard line: sperm enrichment for X spermatozoa is medically necessary in exactly one scenario, and everything else gets denied. The policy covers CPT codes for sperm isolation (89261), flow cytometry (88184, 88185, 88187–88189), artificial insemination (58321, 58322), and IVF-related HCPCS codes S4011–S4042. If your practice bills reproductive procedures for Aetna members, the distinction between medical necessity and elective sex selection will determine whether claims pay or deny.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Preconceptional Sex Selection Techniques
Policy Code	CPB 0323
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium
Specialties Affected	Reproductive endocrinology, fertility clinics, clinical genetics, laboratory medicine
Key Action	Confirm X-linked genetic indication is documented before billing flow cytometry or sperm enrichment procedures — no documentation means automatic denial

---

Aetna Preconceptional Sex Selection Coverage Criteria and Medical Necessity Requirements 2025

The Aetna preconceptional sex selection coverage policy is narrow by design. Aetna considers sperm enrichment for X spermatozoa medically necessary only when the goal is to prevent the birth of a male child to a woman who is a confirmed heterozygous carrier of a seriously handicapping X-linked condition.

The policy cites Lesch-Nyhan disease as its example. But the criteria extend to any seriously handicapping X-linked disorder where the carrier status is documented. This is a genetic medicine question before it's a billing question — the clinical record must establish carrier status before any procedure code makes sense.

Here's the core medical necessity test: carrier confirmed, condition qualifies as seriously handicapping, and the intervention is sperm enrichment for X spermatozoa. All three boxes must be checked. Miss one, and the claim fails medical necessity review.

Prior authorization requirements are not explicitly detailed in CPB 0323, but given Aetna's standard handling of reproductive and genetic procedures, treat any claim touching S4011–S4042 or CPT 89261 as a prior auth candidate. Check the member's specific plan before you schedule. IVF-related services in particular carry prior authorization requirements under most Aetna commercial plans.

Reimbursement for genetic counseling — billed under CPT 96040 or HCPCS S0265 — is separately addressed in the code set. If the patient sees a genetics counselor as part of carrier evaluation, capture those encounters. They support the medical necessity record and may be separately reimbursable.

---

Aetna Preconceptional Sex Selection Exclusions and Non-Covered Indications

This is where CPB 0323 does its real work. Aetna explicitly excludes IVF and intracytoplasmic sperm injection (ICSI) when the sole indication is sex selection — even if a genetic condition is involved downstream.

The policy draws a clear line: if the reason for IVF or ICSI is sex selection rather than prevention of a seriously handicapping genetic defect, the procedure is not treatment of disease. Aetna will not cover it.

This matters for billing teams at fertility clinics. A patient may have a legitimate carrier status and still not meet coverage criteria if the provider documents IVF as the method and the chart doesn't clearly tie the indication to disease prevention. The distinction between "sex selection" and "disease prevention" is a documentation problem as much as a clinical one.

HCPCS codes S4011–S4042 cover IVF and related services across the full spectrum of procedures. Every one of those codes is at risk of denial if the indication documented in the chart reads as elective sex selection rather than prevention of X-linked disease.

The same logic applies to CPT 58976 (gamete, zygote, or embryo intrafallopian transfer) and CPT 58974 (embryo transfer, intrauterine). These procedures may be part of an otherwise covered treatment plan, but if the claim gets reviewed and the chart shows sex selection as the indication, Aetna will deny.

---

Coverage Indications at a Glance

---

Aetna Preconceptional Sex Selection Billing Guidelines and Action Items 2025

These steps apply specifically to claims billed on or after the effective date of September 26, 2025.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Preconceptional Sex Selection Under CPB 0323

CPT Codes — All Codes Listed in CPB 0323

HCPCS Codes — All IVF and Related Codes Listed in CPB 0323

Note on ICD-10 codes: CPB 0323 does not list specific ICD-10-CM diagnosis codes. Work with your clinical team to identify the appropriate ICD-10 codes for the specific X-linked condition documented in the chart — the diagnosis code must match the carrier status and named condition in the medical record.

---

A Note on the S4011–S4042 Code Range

Thirty-two HCPCS codes covering IVF and related services are listed in this policy. Aetna's source document groups all of them under the same generic description. This is not a billing guidelines oversight on our part — that's how the policy is written.

The real issue is that this range covers everything from egg retrieval to embryo cryopreservation to laboratory procedures. When Aetna reviews a claim from this range, the coverage decision turns entirely on the indication documented in the chart. Same code, two different indications — one pays, one doesn't.

Your billing team should treat every S40XX claim for an Aetna member as requiring indication review. Build that into your workflow now, before the September 26, 2025 effective date.

---